JP4206428B1 - Composition for treating dementia and use thereof - Google Patents

Abstract

A composition for treating new dementia is provided.
The composition for treating dementia of the present invention contains an iron preparation, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ , so that a composition for treating new dementia can be provided. .
[Selection figure] None

Description

  The present invention relates to a composition for treating dementia such as Alzheimer's disease and the use thereof.

  Dementia is a mental illness that mainly exhibits cognitive decline or personality change. Among them, Alzheimer's disease, which is a type of dementia, is said to account for more than half of dementia.

  In addition, there are two types of Alzheimer's disease: Familial Alzheimer's disease (Familial AD; FAD) and Alzheimer's type senile dementia of Alzheimer type (SDAT). Familial Alzheimer's disease develops in a younger age group of 30-60 years old, and accounts for a very small number of Alzheimer's disease. Alzheimer-type senile dementia occupies most of Alzheimer's disease patients and is usually considered to develop at the age of 60 years or older.

  The risk factors for developing Alzheimer's disease are said to be related to, for example, age, family history, hypertension, diabetes, hyperlipidemia, smoking, and lifestyle habits, but have certain causative genes. It is known that the risk of onset increases due to (Non-patent Document 1). So far, the amyloid precursor protein (APP) 717 point mutation of chromosome 21 has been discovered as the causative gene, and then the preserin 1 and 2 genes on chromosomes 1 and 12 and on chromosome 19 The apoE gene has been identified. These genes have an effect of inhibiting the degradation of β-amyloid protein, which is considered to be one of the causes of Alzheimer's disease in recent years.

  Normally, β-amyloid produced in the brain is immediately degraded, but the above-mentioned gene holders inhibit the degradation of β-amyloid and accumulate in the brain. Therefore, β amyloid accumulated in the brain kills nerve cells and decreases the secretion amount of various neurotransmitters. As a result, it is difficult to smoothly perform nerve transmission in the brain, and it is said that the cognitive function is hindered. So far, various studies have been made on the mechanism by which β-amyloid kills nerve cells, and among them, attention has been focused on whether β-amyloid is involved in metabolic activity in mitochondria.

  Until now, donepezil hydrochloride (Aricept) has been generally used as a drug for treating Alzheimer's disease. Since this drug can suppress the degradation of acetylcholine, which is a neurotransmitter present in the brain, it has an effect of improving Alzheimer's disease.

On the other hand, a technique aimed at treating Alzheimer's disease by improving metabolic activity in mitochondria has also been studied, and the present inventors have developed three drugs of iron, vitamin B ₆ , and coenzyme Q _10. It has been found that an excellent therapeutic effect for Alzheimer's disease can be obtained by using in combination (Patent Document 1). In addition, as a therapeutic agent for Alzheimer's disease with few side effects, a preventive / therapeutic agent for amnesia (Patent Document 2) containing carnosic acid or rosmarinic acid as an active ingredient and further containing vitamins is known.
Japanese Patent Laid-Open No. 4-112823 (published on April 14, 1992) Japanese Patent Laying-Open No. 2006-199666 (released on August 3, 2006)

  As described above, various therapeutic agents for Alzheimer's disease have been developed, but Alzheimer's disease has not been eradicated.

  In view of such circumstances, a conventionally known Alzheimer's disease therapeutic agent alone is not sufficient, and development of a new Alzheimer's disease therapeutic agent is strongly demanded.

That is, the present inventor conducted further clinical trials after the patent (Patent No. 3064360, Patent Document 1) related to the therapeutic agent using the above-mentioned iron agent, vitamin B ₆ and coenzyme Q ₁₀ in combination. I did it. As a result, it was clarified that, although a remarkable improvement effect was once recognized by administering the three agents to the treatment subject, the effect gradually decreased after a certain period of time after the administration.

  Therefore, an object of the present invention is to provide a composition for treating new dementia and use thereof.

The present inventors have intensively studied to solve the above problems. As a result, it has been found that a new therapeutic effect for dementia can be seen by further using vitamin B ₁ in addition to iron, vitamin B ₆ , and coenzyme Q ₁₀ , and the present invention has been completed. It was. The present invention has been completed based on such novel findings, and includes the following inventions.

In order to solve the above problems, a composition for treating dementia according to the present invention is characterized by containing an iron preparation, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ .

  In the composition for treating dementia according to the present invention, the dementia is preferably familial Alzheimer's disease or Alzheimer's senile dementia. Furthermore, it is preferable to have dementia including cerebrovascular dementia. This is due to the remarkable therapeutic effect of the composition according to the invention, in particular in terms of improving verbal memory and operative memory.

Moreover, the composition for treating dementia according to the present invention is characterized by containing vitamin B ₁ intended for patients administered with iron, vitamin B ₆ , and coenzyme Q ₁₀ .

  Moreover, the food-drinks which concern on this invention are characterized by including the composition for treating the dementia which concerns on the said invention.

Since the composition for treating dementia according to the present invention contains iron, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ as described above, a composition for treating new dementia is provided. There is an effect that it can be provided.

  An embodiment of the present invention will be described as follows.

[1. Composition according to the present invention]
The composition for treating dementia according to the present invention may contain an iron preparation, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ . As used herein, the term “composition” refers to a form in which various components are contained in one substance.

  The composition according to the present invention can be used to treat dementia. Dementia is a psychiatric disorder in which a normally developed brain exhibits progressive intellectual and behavioral disorders due to acquired brain organic disorders. This dementia can be roughly classified into cerebrovascular dementia or Alzheimer type dementia (hereinafter sometimes referred to as “Alzheimer's disease”). The term “treatment” as used herein is treated as including various medically and / or pharmaceutically effective effects such as treatment, prevention, improvement, and prevention of worsening of symptoms.

Further, the present invention contained in the composition according to, iron, vitamin B _6, as the coenzyme Q ₁₀ and vitamin B _1,, may be a known compound which is generally known. That is, the iron agent that can be used is not particularly limited. For example, sodium ferrous citrate, ferrous sulfate, ferric chloride, ferrous citrate, sodium EDTA, ferrous gluconate, iron lactate, pyrroline Examples thereof include ferrous acid and ferric pyrophosphate. Vitamin B ₆ preparation usable are not particularly limited, for example, be mentioned pyridoxine hydrochloride and pyridoxal phosphate. Available Coenzyme Q ₁₀ formulations is not particularly limited, include ubidecarenone. Vitamin B ₁ formulation can be used is not particularly limited, for example, in the vitamin B ₁ salt include thiamin nitrate, hydrochloride Setochiamin (hydrochloride dicethiamine) for vitamins B ₁ derivatives, oct thiamine, thiamine disulfide, bisbentiamine, Examples include fursultiamine, prosultiamine, and benfotiamine.

  Since the composition according to the present invention contains these four compounds, a new therapeutic effect for dementia can be obtained.

For example, by administering the composition according to the present invention to a severe Alzheimer's disease patient, compared with the case where the conventional three components of iron, vitamin B ₆ , and coenzyme Q ₁₀ are administered in combination, the treatment is further prolonged. The symptom improvement effect can be maintained throughout.

  In the composition according to the present invention, it is preferable to treat familial Alzheimer's disease or Alzheimer's senile dementia among dementia, and it is more preferable to have dementia including cerebrovascular dementia. Treating familial Alzheimer's disease or Alzheimer's senile dementia with the composition according to the present invention provides a further remarkable improvement effect compared to treating other dementias. In addition, since the therapeutic effect of the composition according to the present invention is particularly remarkable in terms of improving verbal memory and operative memory, an improvement effect can be obtained for dementia including cerebrovascular dementia.

  Further, the composition according to the present invention can be applied to mammals (human, mouse, rat, rabbit, dog, cat, cow, horse, pig, monkey, etc.).

In the composition according to the present invention, the contents of the iron preparation, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ are not limited. For example, the composition according to the present invention is a patient in the form of a preparation. In the case of administration, the content may be set in accordance with the daily dose of each active ingredient exemplified below.

The composition according to the present invention may be a mixture of an iron preparation, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ as it is, but may also contain a pharmaceutically acceptable carrier. As a manufacturing method of the composition which concerns on this invention, it can manufacture according to a well-known means as a manufacturing method of a pharmaceutical composition, for example.

  In one embodiment, the composition according to the invention may be a pharmaceutical composition. The pharmaceutically acceptable carrier used in the pharmaceutical composition can be selected depending on the dosage form and dosage form of the pharmaceutical composition.

  As used herein, pharmacologically acceptable carriers include various organic or inorganic carrier materials that can be used as pharmaceutical materials, and include excipients, lubricants, binding agents in solid formulations. Or a disintegrant, or a solvent, a solubilizing agent, a suspending agent, an isotonic agent, a buffering agent, or a soothing agent in a liquid preparation.

  Examples of excipients include lactose, sucrose, D-mannitol, xylitol, sorbitol, erythritol, starch, and crystalline cellulose. Lubricants include, for example, magnesium stearate, calcium stearate, talc, and Examples thereof include colloidal silica.

  Examples of the binder include pregelatinized starch, methylcellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, and polyvinylpyrrolidone.

  Examples of the disintegrant include starch, carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, and carboxymethyl starch sodium.

  Examples of the solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and tricaprylin.

  Examples of the solubilizer include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, and sodium citrate.

  Examples of the suspension include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate, or polyvinyl alcohol, polyvinylpyrrolidone, carboxy Examples include hydrophilic polymers such as sodium methylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose.

  Examples of isotonic agents include sodium chloride, glycerin, and D-mannitol.

  Examples of the buffer include buffer solutions such as phosphate, acetate, carbonate, and citrate.

  Examples of soothing agents include benzyl alcohol.

  Examples of the preservative include p-hydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid.

  Examples of the antioxidant include sulfite and ascorbic acid.

The pharmaceutical composition which concerns on this embodiment can be manufactured in accordance with a method conventionally used in the formulation technical field. The content of iron preparation, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B _{1 in} the pharmaceutical composition according to the present embodiment is based on the dosage form, administration method, etc., and the dosage range described below using the pharmaceutical composition. However, there is no particular limitation as long as it can administer iron, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ .

  Examples of the dosage form of the pharmaceutical composition according to this embodiment include tablets, capsules (including soft capsules and microcapsules), powders, granules, syrups and other oral preparations, or injections, suppositories, and pellets. And parenteral agents such as drops. The term “parenteral” as used herein refers to modes of administration including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, and intraarticular injections and infusions.

  The dosage of the pharmaceutical composition according to the present embodiment varies depending on the administration subject, administration route, symptom, and the like, but those skilled in the art appropriately set optimal conditions according to the administration subject, administration route, symptom, etc. be able to.

  The pharmaceutical composition according to the present embodiment can be administered by an appropriate administration route according to the preparation form. The administration method is not particularly limited, and can be applied by internal use, external use or injection. The injection can be administered, for example, intravenously, intramuscularly, subcutaneously, and intradermally.

The dosage of the pharmaceutical composition according to the present embodiment is appropriately set according to the formulation form, administration method, purpose of use, and age, weight, and symptom of the patient to whom the pharmaceutical is administered, and is not constant. For example, the dosage for adults per day of each active ingredient contained in the formulation, the iron is 50 to 250 mg, preferably 100 to 250 mg, more preferably from 100 to 150 mg, 40～210Mg the vitamin _{B 6} , Preferably 180 to 210 mg, coenzyme Q ₁₀ is 60 to 180 mg, preferably 60 to 120 mg, and vitamin B ₁ is 140 to 280 mg, preferably 210 to 235 mg. Moreover, you may adjust the dosage of each component according to a symptom. For example, for patients with mild symptoms, the dose of each component may be the lower limit of the range exemplified here, and for patients with severe symptoms, the dose of each component is the range exemplified here. It is good also as each upper limit of. Of course, since the dosage varies depending on various conditions, an amount smaller than the above dosage may be sufficient or may be necessary beyond the range. Administration may be performed once or divided into several times within one day within a desired dose range. Moreover, the pharmaceutical composition according to the present embodiment can be orally administered as it is, or can be added to any food or drink and taken daily.

The compositions according to the present invention, iron, vitamin B _6, and directed to a coenzyme Q ₁₀ treated patients, may include vitamin B _1. That is, a composition containing vitamin B ₁ may be administered to a patient who is administered iron, vitamin B ₆ , and coenzyme Q ₁₀ . Thus, iron, vitamin B _6, and the effect of improving dementia 3 component of patients administered of coenzyme Q _10, can be maintained over a long term. Incidentally, iron, vitamin _{B 6,} and the coenzyme _{Q 10} treated patients, the purpose of administering iron, vitamin _{B 6,} and coenzyme _{Q 10} is meant patients administered, iron, vitamin _{B 6,} and coenzyme _{Q 10} It is not limited to the treatment of dementia.

[2. Food and drink according to the present invention]
The food-drinks which concern on this invention should just contain the composition for treating the dementia which concerns on the said invention. Since the food-drinks which concern on this invention contain the composition which concerns on the said invention, the new effect for treating dementia can be anticipated.

  When the composition of the present invention is used for foods and drinks, it is prepared as it is, in a form diluted with oil, a milk form meal, or a form to which a carrier generally used in the food industry is added. May be.

  As an emulsion form, for example, a composition is added to the oil phase part, and liquid fats such as glycerin fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, glycerol, dextrin, rapeseed oil, soybean oil, corn oil and the like are added. In addition, L-ascorbic acid or an ester or salt thereof, for example, gum such as locust bean gum, gum arabic or gelatin, for example, flavonoids such as hesperidin, rutin, quercetin, catechin, thianidine or polyphenols or a mixture thereof Etc. can be added and emulsified.

  In the form of a beverage, for example, it may be a non-alcoholic beverage or an alcoholic beverage. Examples of non-alcoholic drinks include non-carbonated drinks such as carbonated drinks, fruit juice drinks, and nectar drinks, soft drinks, sports drinks, tea, coffee, and cocoa. Moreover, as a form of alcoholic drink, the form of general foods, such as spirits, liqueur, chuhai, fruit liquor, malt liquor, happoshu, and medicinal liquor, can be illustrated, for example.

  Examples of food and drink include confectionery (pudding, jelly, gummy candy, candy, drop, caramel, chewing gum, chocolate, pastry, butter cream, custard cream, cream puff, hot cake, bread, potato chips, french fries, popcorn, Biscuits, crackers, pies, sponge cakes, castella, waffles, cakes, donuts, biscuits, cookies, rice crackers, rice cakes, rice cakes, manju, candy etc., dried noodle products (macaroni, pasta), egg products (mayonnaise, fresh cream) , Beverages (functional beverages, lactic acid beverages, lactic acid bacteria beverages, concentrated milk beverages, fruit juice beverages, fruit juice beverages, fruit beverages, transparent carbonated beverages, carbonated beverages with fruit juice, fruit colored carbonated beverages), luxury products (green tea, tea, Instant coffee, Core, canned coffee drink), dairy products (ice cream, yogurt, coffee milk, butter, butter sauce, cheese, fermented milk, processed milk), pastes (marmalade, jam, flower paste, peanut paste, fruit paste, Fruit syrup), livestock products (ham, sausage, bacon, dry sausage, beef jerky, lard), seafood products (fish ham, fish sausage, salmon, chikuwa, hampen, fish dried fish, bonito, bonito, boiled and dried , Sea urchin, sea cucumber salted fish, dried squid, dried fish shellfish, dried fish shellfish, salmon products), boiled fish (small fish, shellfish, wild vegetables, sea bream, kelp), curry (instant curry, retort curry, canned curry) ), Seasonings (Miso, powdered miso, soy sauce, powdered soy sauce, moromi, fish sauce, sauce, ketchup, oyster -Sauce, solid bouillon, grilled meat sauce, curry roux, stew sauce, soup sauce, soup stock, paste, instant soup, sprinkle, dressing, salad oil), fried products (fried food, fried confectionery, instant ramen), soy milk, margarine And shortening. In addition, the said food-drinks can be processed and manufactured by mix | blending a composition with the raw material of a general food according to a conventionally well-known manufacturing method.

  Moreover, the said food-drinks can be used as a functional food, a dietary supplement, or health food, for example. The form is not particularly limited, and examples of food production include milk proteins with high amino acid balance, soy protein, and proteins such as egg albumin, degradation products thereof, and egg white oligos. In addition to peptides, soybean hydrolysates, and the like, mixtures of amino acids alone can be used according to conventionally known methods. It can also be used in the form of a soft capsule, a tablet or the like.

  Examples of dietary supplements or functional foods include liquid foods, semi-digested nutritional foods, ingredient nutritional foods, drinks, capsules, and sucrose containing sugars, fats, trace elements, vitamins, emulsifiers, and fragrances. Processing forms such as enteral nutrients can be mentioned. In the above-mentioned various foods, for example, foods and drinks such as sports drinks and nutritional drinks are further supplemented with nutritional additives such as amino acids, vitamins and minerals, sweeteners, spices and fragrances to improve nutritional balance and flavor. Or a pigment | dye etc. can also be mix | blended.

  In addition, an antioxidant or the like may be used to stabilize the composition of the present invention. For example, tocopherol, L-ascorbic acid, BHA, rosemary extract and the like may be used in combination according to a conventionally known method. it can.

  Moreover, in the food / beverage products which concern on this invention, it does not specifically limit as content of the composition concerning this invention.

Thus, it can be said that the composition according to the present invention should contain at least an iron preparation, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ . That is, it should be noted that a drug containing a plurality of iron preparations, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ is also included in the technical scope of the present invention.

  Examples will be shown below, and the embodiments of the present invention will be described in more detail. Of course, the present invention is not limited to the following examples, and it goes without saying that various aspects are possible in detail. Further, the present invention is not limited to the above-described embodiments, and various modifications can be made within the scope shown in the claims, and the present invention is also applied to the embodiments obtained by appropriately combining the disclosed technical means. It is included in the technical scope of the invention. Moreover, all the patent documents and nonpatent literatures described in this specification are used as reference in this specification.

<Example 1>
The composition of this example was prepared as follows. That is, 100-150 mg of ferrous sodium citrate, 40-180 mg of vitamin B ₆ , 120 mg of coenzyme Q ₁₀ (3 minutes administration), and 210-235 mg of vitamin B ₁ were weighed and filled into capsules. The content of each component in the composition is, for example, the lower limit of the content of each component for patients with mild cognitive impairment, and the content of each component for patients with severe AD. It was set as the upper limit value. For patients with mild AD and moderate AD, sodium ferrous citrate 100 mg, 100-150 mg, vitamin B ₆ 100 mg, 100-180 mg, vitamin B ₁ 210 mg, 210-235 mg, respectively. did.

  The composition thus prepared was administered to the subject. The subject of this example is a person who has developed Alzheimer's disease or a person who is located in the previous stage, and the degree of symptom progression of each subject is an index based on the following MMSE (mini-mental state examination) test. Using.

  Here, “a person in the pre-stage of Alzheimer's disease” refers to a patient with mild cognitive impairment (MCI), which has recently become a problem. Mild cognitive impairment is a gray zone between Alzheimer's disease and a healthy state and is positioned in the pre-stage of Alzheimer's disease. For example, in the MMSE test shown below, even if it is “normal” of 24-30 points, about half of them are said to develop Alzheimer's disease if they are accompanied by mild cognitive impairment such as forgetfulness (forgetfulness). .

  The MMSE test is widely used worldwide as a screening test for dementia, and consists of 11 questions shown in FIG. FIG. 1 shows the questions in the MMSE inspection. An overall score was derived from the MMSE test responses, and the degree of symptom progression was determined. Specifically, when all questions are answered correctly, the score is 30 points. When the total score is 21 points or less, it is determined that there is a high possibility that there is a cognitive disorder such as dementia. Among them, the severity is classified into three levels, with 23 to 20 points for mild, 19 to 10 for moderate, and 9 to 0 for severe. Moreover, even if it was 24-30 points | pieces, when mild cognitive impairment accompanied, it was handled as mild cognitive impairment. Based on this index, subjects at each stage were extracted and the composition of this example was administered for 12 months. The extracted subjects were 4 males (59-71 years old) and 8 females (57-81 years old).

  Moreover, the determination of the therapeutic effect on Alzheimer's disease and MCI patients was also performed by the MMSE test described above. The test was performed before administration and at 1 month, 3 months, 6 months, 8 months and 12 months after the start of administration. The results thus obtained are shown in Table 1 below.

  In the table, FA, MM, MT, HN, YI, MR, HT, TY, NS, TS, and IK represent the initials of the subject. AD represents Alzheimer's disease.

  Moreover, the graph which showed this result is shown in FIGS. FIG. 2 is a graph showing changes in scores of MMSE tests performed on mild AD patients administered with the composition of the example or the composition of the comparative example, and FIG. 3 shows the transition of the composition of the example or the comparative example. FIG. 4 is a graph showing changes in scores of MMSE tests performed on moderate AD patients administered with the composition, and FIG. 4 was performed on severe AD patients administered with the composition of the example or the comparative composition. It is a graph showing transition of the score of a MMSE test | inspection. FIG. 5 is a graph showing changes in scores of MMSE examinations performed on MCI patients administered with the compositions of the examples.

  As shown in this table, the MMSE test scores increased by 1 to 5 points from all subjects who received the composition of the examples from before the start to 1 month after the administration. Thereafter, at the time when 3 months, 6 months, and 8 months passed, all were higher than or equal to 1 month after administration. In addition, YI and TY, which are moderate AD patients, TS and IK, which are severe AD patients, and mild cognitive impairment FA, were higher than or equal to those after one month even after 12 months.

  From these results, it was found that in the composition of this example, the therapeutic effect on Alzheimer's disease patients and MCI patients was observed at any stage of progression, and the effect could be further maintained for up to 8 months or 12 months.

<Comparative example>
In the comparative example, 100-150 mg of ferrous sodium citrate, 40-180 mg of vitamin B ₆ and 120 mg of coenzyme Q ₁₀ (3 minutes administration) were weighed and filled into capsules. In the comparative example, the content of each component in the composition is, for example, a lower limit for the content of each component for patients with mild cognitive impairment, and for patients with severe AD It was set as the upper limit in content of each component. For patients with mild AD and moderate AD, sodium ferrous citrate 100 mg, 100-150 mg, vitamin B ₆ 100 mg, 100-180 mg, vitamin B ₁ 210 mg, 210-235 mg, respectively. did. Moreover, the subject in the comparative example was 30 patients with mild AD, 88 patients with moderate AD, and 46 patients with severe AD.

  The results of administration of the composition of this comparative example to Alzheimer's disease patients and MCI patients are shown in FIGS.

  As shown in FIG. 2, in mild AD patients to which the composition of the comparative example was administered, it increased by 1.5 points in one month after the start, and further increased by 1.8 points from the start after 6 months. I found out. However, it has been on a downward trend since then, and after 12 months it has fallen to the same value as in the third month.

  In moderate AD patients to which the composition of the comparative example was administered, as shown in FIG. 3, it was found that it increased by about 3 points in 1 month after the start, but gradually decreased after 6 months.

  In addition, in severe AD patients administered with the composition of the comparative example shown in FIG. 4, it was found that it increased by about 3 points in 1 month after the start, but gradually decreased immediately thereafter.

  FIG. 5 is a graph showing the transition of MMSE of two mild cognitive impairment patients who are located in the previous stage of Alzheimer's disease, which has recently become a problem, and about half of which are said to shift to Alzheimer's disease. Although this comparative example is an example, it is once improved as in the other groups, but after that, there is a tendency to gradually decrease with time. On the other hand, it is noteworthy that the Examples improve to normal values immediately after administration of the composition and no decrease is observed thereafter.

  From the above results, in the compositions of the examples, there is no sign that the symptoms once recovered even after 8 months or 12 months have passed, so the development of treatment for Alzheimer's disease using the composition of the present invention is not possible. It is what you expect.

  According to the composition according to the present invention, for example, a new effect is seen in the treatment of dementia such as familial Alzheimer's disease or Alzheimer's senile dementia, and therefore, it can be suitably used in the pharmaceutical industry or the food industry.

It is a question item of MMSE used for evaluation of dementia in an Example. It is a graph showing transition of the score of the MMSE test | inspection performed to the mild AD patient who administered the composition of the Example or the comparative example. It is a graph showing transition of the score of the MMSE test | inspection performed to the moderate AD patient who administered the composition of the Example or the comparative example. It is a graph showing transition of the score of the MMSE test | inspection performed to the severe AD patient who administered the composition of the Example or the comparative example. It is a graph showing transition of the score of the MMSE test | inspection performed to the mild cognitive impairment (MCI) patient who administered the composition of an Example or a comparative example.

Claims (3)

A composition for treating dementia, comprising iron, vitamin B ₆ , coenzyme Q ₁₀ , and vitamin B ₁ .   The composition for treating dementia according to claim 1, wherein the dementia is familial Alzheimer's disease, Alzheimer's senile dementia or cerebrovascular dementia. Iron, vitamin B _6, and directed to a coenzyme Q ₁₀ treated patients, compositions for treating dementia, which comprises a vitamin B _1.

Images